Xeris Biopharma Share Price Today
(NASDAQ: XERS)

Name: Xeris Biopharma Share Price Today (NASDAQ: XERS) - Xeris Biopharma Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Xeris Biopharma share price is $3.64 & ₹317.03 as on 5 Feb 2025, 2.30 'hrs' IST

$3.64

▲

0.05

(1.39%)

Market is closed - opens 8 PM, 05 Feb 2025

View live Xeris Biopharma share price in Dollar and Rupees. Guide to invest in Xeris Biopharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Xeris Biopharma, along with analyst recommendations, forecasts, and comprehensive financials.

Xeris Biopharma share price movements

Today's Low: $3.55
Today's High: $3.67
$3.64
2.47%
Downside
Day's Volatility :3.27%
Upside
0.82%
52 Weeks Low: $1.69
52 Weeks High: $3.87
$3.64
53.57%
Downside
52 Weeks Volatility :56.33%
Upside
5.94%

Xeris Biopharma (XERS) Returns

Period	Xeris Biopharma Holdings Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	8.98%	-0.5%	0.0%
6 Months	70.89%	0.1%	0.0%
1 Year	37.88%	3.2%	0.0%
3 Years	100.0%	11.1%	-11.7%

Xeris Biopharma (XERS) Key Statistics

in dollars & INR

Previous Close	$3.59
Open	$3.58
Today's High	$3.67
Today's Low	$3.55
Market Capitalization	$542.7M
Today's Volume	$994.8K
52 Week High	$3.87
52 Week Low	$1.69
Revenue TTM	$187.4M
EBITDA	$-33.1M
Earnings Per Share (EPS)	$-0.43
Profit Margin	-33.69%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-617.16%

How to invest in Xeris Biopharma Stock (XERS) from India?

It is very easy for Indian residents to invest directly in Xeris Biopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Xeris Biopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Xeris Biopharma or XERS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Xeris Biopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Xeris Biopharma shares which would translate to 0.239 fractional shares of Xeris Biopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Xeris Biopharma, in just a few clicks!

Returns in Xeris Biopharma (XERS) for Indian investors in Rupees

The Xeris Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Xeris Biopharma investment value today

Current value as on today

₹1,42,782

Returns

₹42,782

(+42.78%)

Returns from Xeris Biopharma Stock

₹37,879 (+37.88%)

Dollar Returns

₹4,903 (+4.9%)

Indian investors sentiment towards Xeris Biopharma (XERS)

-46%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Xeris Biopharma Stock from India on INDmoney has decreased by -46% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Xeris Biopharma

BlackRock Inc
7.20%
Vanguard Group Inc
5.21%
Caxton Corp
3.43%
CenterBook Partners LP
2.34%
Geode Capital Management, LLC
2.24%
State Street Corp
2.15%

Analyst Recommendation on Xeris Biopharma

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Xeris Biopharma(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Xeris Biopharma Stock (XERS)

What analysts predicted

Upside of 40.11%

Target:

$5.10

Current:

$3.64

Insights on Xeris Biopharma Stock (Ticker Symbol: XERS)

Price Movement
In the last 6 months, XERS stock has moved up by 63.2%
Increasing Revenue
Revenue is up for the last 3 quarters, 40.63M → 54.26M (in $), with an average increase of 13.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -15.00M → -15.73M (in $), with an average decrease of 4.9% per quarter
XERS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.8% return, outperforming this stock by 11.4%
Price to Sales
ForXERS every $1 of sales, investors are willing to pay $2.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.4 for every $1 of sales.

XERS Xeris Biopharma Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$2.5M	↑ 58.42%
Net Income	$-60.1M	↑ 126.26%
Net Profit Margin	-2.4K%	↓ 730.76%

	FY19	Y/Y Change
Revenue	$2.7M	↑ 10.43%
Net Income	$-125.6M	↑ 109.02%
Net Profit Margin	-4.6K%	↓ 2176.2%

	FY20	Y/Y Change
Revenue	$20.2M	↑ 640.45%
Net Income	$-91.1M	↓ 27.42%
Net Profit Margin	-452.2%	↑ 4161.32%

	FY21	Y/Y Change
Revenue	$110.2M	↑ 447.0%
Net Income	$-94.7M	↑ 3.86%
Net Profit Margin	-85.86%	↑ 366.34%

	FY22	Y/Y Change
Revenue	$110.2M	↑ 0.0%
Net Income	$-94.7M	↑ 0.0%
Net Profit Margin	-85.86%	↑ 0.0%

	FY23	Y/Y Change
Revenue	$163.9M	↑ 48.68%
Net Income	$-62.3M	↓ 34.23%
Net Profit Margin	-37.98%	↑ 47.88%

	Q2 FY23	Q/Q Change
Revenue	$38.0M	↑ 14.5%
Net Income	$-19.8M	↑ 17.87%
Net Profit Margin	-52.2%	↓ 1.49%

	Q3 FY23	Q/Q Change
Revenue	$48.3M	↑ 27.13%
Net Income	$-12.2M	↓ 38.57%
Net Profit Margin	-25.23%	↑ 26.97%

	Q4 FY23	Q/Q Change
Revenue	$44.4M	↓ 8.13%
Net Income	$-13.4M	↑ 9.85%
Net Profit Margin	-30.16%	↓ 4.93%

	Q1 FY24	Q/Q Change
Revenue	$40.6M	↓ 8.45%
Net Income	$-19.0M	↑ 41.75%
Net Profit Margin	-46.71%	↓ 16.55%

	Q2 FY24	Q/Q Change
Revenue	$48.1M	↑ 18.28%
Net Income	$-15.0M	↓ 20.94%
Net Profit Margin	-31.22%	↑ 15.49%

	Q3 FY24	Q/Q Change
Revenue	$54.3M	↑ 12.91%
Net Income	$-15.7M	↑ 4.89%
Net Profit Margin	-29.0%	↑ 2.22%

	FY18	Y/Y Change
Profit	$2.4M	↑ 56.12%

	FY19	Y/Y Change
Profit	$1.1M	↓ 53.82%

	FY20	Y/Y Change
Profit	$10.8M	↑ 867.56%

	FY21	Y/Y Change
Profit	$87.6M	↑ 709.22%

	FY22	Y/Y Change
Profit	$87.6M	↑ 0.0%

	FY23	Y/Y Change
Profit	$135.3M	↑ 54.39%

	Q2 FY23	Q/Q Change
Profit	$30.5M	↑ 9.24%

	Q3 FY23	Q/Q Change
Profit	$40.1M	↑ 31.74%

	Q4 FY23	Q/Q Change
Profit	$34.1M	↓ 14.98%

	Q1 FY24	Q/Q Change
Profit	$32.0M	↓ 6.31%

	Q2 FY24	Q/Q Change
Profit	$37.6M	↑ 17.55%

	Q3 FY24	Q/Q Change
Profit	$40.7M	↑ 8.28%

	FY18	Y/Y Change
Operating Cash Flow	$-56.3M	↑ 128.19%
Investing Cash Flow	$-68.3M	↑ 9651.57%
Financing Cash Flow	$128.2M	↑ 264.87%

	FY19	Y/Y Change
Operating Cash Flow	$-104.3M	↑ 85.41%
Investing Cash Flow	$-2.4M	↓ 96.51%
Financing Cash Flow	$80.5M	↓ 37.19%

	FY20	Y/Y Change
Operating Cash Flow	$-80.6M	↓ 22.8%
Investing Cash Flow	$-27.4M	↑ 1050.02%
Financing Cash Flow	$126.1M	↑ 56.54%

	FY21	Y/Y Change
Operating Cash Flow	$-95.5M	↑ 18.59%
Investing Cash Flow	$98.0M	↓ 457.47%
Financing Cash Flow	$27.2M	↓ 78.39%

	FY22	Y/Y Change
Operating Cash Flow	$-102.9M	↑ 7.7%
Investing Cash Flow	$34.5M	↓ 64.82%
Financing Cash Flow	$127.5M	↑ 367.84%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-13.7M	↓ 47.42%
Investing Cash Flow	$8.5M	↑ 0.0%
Financing Cash Flow	$556.0K	↓ 164.43%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-14.6M	↑ 6.3%
Investing Cash Flow	$14.7M	↑ 73.39%
Financing Cash Flow	$-72.0K	↓ 112.95%

Xeris Biopharma Technicals Summary

Sell

Neutral

Buy

Xeris Biopharma is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Xeris Biopharma (XERS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Xeris Biopharma Holdings Inc	2.82%	70.89%	37.88%	100.0%	100.0%
Biontech Se	-2.55%	47.81%	22.02%	-32.21%	279.34%
Regeneron Pharmaceuticals, Inc.	-2.68%	-34.72%	-25.67%	12.0%	82.54%
Vertex Pharmaceuticals Incorporated	19.82%	3.52%	15.9%	98.26%	100.9%
Alnylam Pharmaceuticals, Inc.	16.23%	4.16%	57.39%	82.31%	115.97%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Xeris Biopharma Holdings Inc	NA	NA	NA	-0.24	-6.17	-0.09	NA	-0.19
Biontech Se	160.8	NA	0.04	-3.37	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.49	16.49	1.08	44.92	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Xeris Biopharma Holdings Inc	Buy	$542.7M	100.0%	NA	-33.69%
Biontech Se	Buy	$28.7B	279.34%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$73.3B	82.54%	16.49	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$121.1B	100.9%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.4B	115.97%	NA	-15.86%

About Xeris Biopharma

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Organization	Xeris Biopharma
Employees	377
CEO	Mr. John P. Shannon
Industry	Health Technology

Management People of Xeris Biopharma

Name	Title
Mr. John P. Shannon	CEO & Director
Mr. Steven M. Pieper	Chief Financial Officer
Ms. Beth P. Hecht J.D.	Chief Legal Officer & Corporate Secretary
Mr. Paul R. Edick J.D.	Senior Advisor
Dr. Kenneth E. Johnson Pharm. D., Pharm.D.	Senior VP of Global Development & Medical Affairs
Ms. Allison Wey	Senior Vice President of Investor Relations & Corporate Communications
Mr. Brian Conner	SVP of Quality and Chief Compliance & Risk Officer
Ms. Kendal Korte	Senior Vice President of Human Resources
Mr. Kevin McCulloch	Chief Commercial Officer

Important FAQs about investing in XERS Stock from India :

What is Xeris Biopharma share price today?

Xeris Biopharma share price today stands at $3.64, Open: $3.58 ; Previous Close: $3.59 ; High: $3.67 ; Low: $3.55 ; 52 Week High: $3.87 ; 52 Week Low: $1.69.

The stock opens at $3.58, after a previous close of $3.59. The stock reached a daily high of $3.67 and a low of $3.55, with a 52-week high of $3.87 and a 52-week low of $1.69.

Can Indians buy Xeris Biopharma shares?

Yes, Indians can invest in the Xeris Biopharma (XERS) from India.

With INDmoney, you can buy Xeris Biopharma at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Xeris Biopharma at zero transaction cost.

How can I buy Xeris Biopharma shares from India?

It is very easy to buy Xeris Biopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Xeris Biopharma (XERS) be purchased?

Yes, you can buy fractional shares of Xeris Biopharma with INDmoney app.

What are the documents required to start investing in Xeris Biopharma stocks?

To start investing in Xeris Biopharma, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.